Related references
Note: Only part of the references are listed.Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETOLOGIA (2015)
How many people inject insulin? UK estimates from 1991 to 2010
S. E. Holden et al.
DIABETES OBESITY & METABOLISM (2014)
National Estimates of Insulin-Related Hypoglycemia and Errors Leading to Emergency Department Visits and Hospitalizations
Andrew I. Geller et al.
JAMA INTERNAL MEDICINE (2014)
Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review
Remy Boussageon et al.
BMC MEDICAL RESEARCH METHODOLOGY (2013)
Hypoglycemia, With or Without Insulin Therapy, Is Associated With Increased Mortality Among Hospitalized Patients
Rajesh Garg et al.
DIABETES CARE (2013)
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial
M. Nauck et al.
DIABETIC MEDICINE (2013)
The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern
C. J. Currie et al.
DIABETES OBESITY & METABOLISM (2012)
Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis
S. -C. Liu et al.
DIABETES OBESITY & METABOLISM (2012)
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial
Pablo Aschner et al.
LANCET (2012)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials
Remy Boussageon et al.
PLOS MEDICINE (2012)
Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes A randomized 26-week study on glycemic control and hypoglycemia
Baptist Gallwitz et al.
DIABETES CARE (2011)
Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?
K. L. Rensing et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial
P. Hollander et al.
DIABETES OBESITY & METABOLISM (2011)
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
Sreenivasa Rao Kondapally Seshasai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Emergency Hospitalizations for Adverse Drug Events in Older Americans
Daniel S. Budnitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Insulin use and increased risk of mortality in type 2 diabetes: a cohort study
J. -M. Gamble et al.
DIABETES OBESITY & METABOLISM (2010)
Mitogenic action of insulin: friend, foe or 'frenemy'?
B. Draznin
DIABETOLOGIA (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Severe Hypoglycemia and Risks of Vascular Events and Death.
Sophia Zoungas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
Denise E. Bonds et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial
Mathijs C. Bunck et al.
DIABETES CARE (2009)
Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study
J. -F. Blickle et al.
DIABETES OBESITY & METABOLISM (2009)
Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
M. J. Davies et al.
DIABETES OBESITY & METABOLISM (2009)
Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expression in adipose tissue in patients with type 2 diabetes
Agnes Hartemann-Heurtier et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes Mellitus
Rachel A. Whitmer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Insulin and insulin-like growth factor signalling in neoplasia
Michael Pollak
NATURE REVIEWS CANCER (2008)
Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes
L. Raymond Reynolds et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
M. A. Nauck et al.
DIABETOLOGIA (2007)
A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study
H. C. Gerstein et al.
DIABETIC MEDICINE (2006)
Triple therapy in type 2 diabetes - Insulin glargine or rosiglitazone added to combmiation therapy of sulfonylurea plus metformin in insulin-naive patients
J Rosenstock et al.
DIABETES CARE (2006)
Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin
SL Bowker et al.
DIABETES CARE (2006)
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial
RJ Heine et al.
ANNALS OF INTERNAL MEDICINE (2005)
Efficacy of biphasic insulin aspart in patients with type 2 diabetes
S Halimi et al.
CLINICAL THERAPEUTICS (2005)
Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients
M Alvarsson et al.
DIABETES CARE (2003)
The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study
RM Ewart
BMJ-BRITISH MEDICAL JOURNAL (2001)
Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data
J McCormack et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
